Benzinga | Apr 27, 2021 08:10AM EDT

Esperion Highlights Publication Of Rationale And Design Of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL Tablet In American Heart Journal

Esperion (NASDAQ:ESPR) today announced the peer reviewed publication of the key design paper outlining the baseline characteristics of the enrolled patient population, rationale and design of the CLEAR Outcomes trial evaluating NEXLETOL(r) (bempedoic acid) Tablet in patients with documented statin intolerance, the first and only cardiovascular outcomes trial (CVOT) to exclusively study this patient population at high risk of cardiovascular disease (CVD), in the May 2021 issue of the American Heart Journal.